SDAM
MRNA icon

Shulman DeMeo Asset Management’s Moderna MRNA Stock Holding History

Shulman DeMeo Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-863
Closed -$219K – 148
2021
Q4 		$219K Buy
+863
New +$252K 0.06% 136
2021
Q3 		– Sell
-919
Closed -$216K – 116
2021
Q2 		$216K Buy
+919
New +$164K 0.08% 58
2021
Q1 		– Sell
-1,940
Closed -$203K – 143
2020
Q4 		$203K Buy
+1,940
New +$196K 0.06% 130

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Shulman DeMeo Asset Management's MRNA Position: Q1 2022 in Review

Shulman DeMeo Asset Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 863 shares — an estimated $219K sold.

Shulman DeMeo Asset Management first reported a position in MRNA in Q4 2020 and held it in 3 quarters. The position peaked at $219K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Shulman DeMeo Asset Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Shulman DeMeo Asset Management sold 863 Moderna shares in Q1 2022, an estimated $219K.
  • Shulman DeMeo Asset Management first reported a position in Moderna in Q4 2020 and held it in 3 quarters.
  • Shulman DeMeo Asset Management's Moderna position peaked at $219K in Q4 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Shulman DeMeo Asset Management's 13F filing for Q1 2022, filed 27 Apr 2022.